| A | B | C | D | E | F | G | H | I | J | K | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | |||||||||||
| 2 | Name | Indication | MOA | Economics | Admin | IP | Price | 27.5 | |||
| 3 | nirogacestat | Desmoid, MM | GSI | PFE | Shares | 58.068182 | Q222 | ||||
| 4 | mirdametinib | NF1 | MEK | MC | 1596.875005 | ||||||
| 5 | BGB-3245 | BRAF | MapKure | Cash | 566.4490000000001 | Q222 | |||||
| 6 | Debt | 0 | Q222 | ||||||||
| 7 | EV | 1030.426005 | |||||||||
| 8 | |||||||||||
| 9 | CEO: Saqib Islam | ||||||||||
| 10 | 9/7/22: $225m financing: 8.6m shares sold at $26.01. |